Technical Analysis for LUCD - Lucid Diagnostics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | -0.50% | |
| Pocket Pivot | Bullish Swing Setup | -0.50% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 4.10% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.10% | |
| NR7 | Range Contraction | 4.10% | |
| Inside Day | Range Contraction | 4.10% | |
| Gapped Down | Weakness | 4.10% | |
| Fell Below 20 DMA | Bearish | 4.74% | |
| MACD Bearish Signal Line Cross | Bearish | 4.74% | |
| 200 DMA Support | Bullish | 4.74% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 1 hour ago |
| Down 1% | about 1 hour ago |
| Possible NR7 | about 1 hour ago |
| 10 DMA Resistance | about 4 hours ago |
| Up 1% | about 4 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Gastroenterology Digestive Diseases Esophageal Cancer
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Cancer Gastroenterology Digestive Diseases Esophageal Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.58 |
| 52 Week Low | 0.6301 |
| Average Volume | 332,444 |
| 200-Day Moving Average | 0.91 |
| 50-Day Moving Average | 0.88 |
| 20-Day Moving Average | 0.97 |
| 10-Day Moving Average | 1.00 |
| Average True Range | 0.06 |
| RSI (14) | 57.63 |
| ADX | 31.62 |
| +DI | 27.54 |
| -DI | 18.18 |
| Chandelier Exit (Long, 3 ATRs) | 0.93 |
| Chandelier Exit (Short, 3 ATRs) | 1.02 |
| Upper Bollinger Bands | 1.07 |
| Lower Bollinger Band | 0.88 |
| Percent B (%b) | 0.64 |
| BandWidth | 20.16 |
| MACD Line | 0.03 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0066 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.11 | ||||
| Resistance 3 (R3) | 1.10 | 1.06 | 1.09 | ||
| Resistance 2 (R2) | 1.06 | 1.03 | 1.06 | 1.08 | |
| Resistance 1 (R1) | 1.03 | 1.02 | 1.05 | 1.04 | 1.08 |
| Pivot Point | 0.99 | 0.99 | 1.00 | 0.99 | 0.99 |
| Support 1 (S1) | 0.96 | 0.96 | 0.98 | 0.97 | 0.92 |
| Support 2 (S2) | 0.92 | 0.95 | 0.92 | 0.92 | |
| Support 3 (S3) | 0.89 | 0.92 | 0.91 | ||
| Support 4 (S4) | 0.90 |
